Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | FFAR3 | O14843 | 11/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13457882 | 0.85 | FFAR3 (0.61) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL10478145 | 0.84 | TDP1 (0.58) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL15859458 | 0.81 | FFAR3 (0.56) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL3263202 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL14010782 | 0.79 | FFAR3 (0.63) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL15866579 | 0.78 | FFAR3 (0.62) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL5065106 | 0.77 | FFAR3 (0.68) | KDM4EFFAR3SMN1; SMN2 | |
| O-Tolylamine SCHEMBL5315045 | 0.76 | FFAR3 (0.52) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL15866594 | 0.76 | FFAR3 (0.66) | KDM4EFFAR3SMN1; SMN2 | |
| SCHEMBL5064866 | 0.74 | FFAR3 (0.76) | KDM4EFFAR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812080-B1 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARM INC (US) | 2014-07-09 | — | — | EP | claimed |
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | claimed |
| EP-1812080-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006052566-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1812080-B1 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARM INC (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2010030997-A1 | REGULATING INTESTINAL MICROBIOTA DEPENDENT SIGNALING AS A MEANS TO MODULATE BODY FAT AND/OR WEIGHT LOSS | THE WASHINGTON UNIVERSITY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1812080-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052566-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | GPR119, GPR4, GLP1R | ALDH1A1 3656/4885KDM4E 3458/4885MAPT 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.